GHK-Cu Dosage Guide: Injectable & Topical Peptide Reconstitution, Half-Life & Research

GHK-Cu research guide covering injectable reconstitution math, topical application context, collagen and angiogenesis mechanism, and syringe unit calculator.

TL;DR

• GHK-Cu is a tripeptide (Glycine-Histidine-Lysine) chelated with a copper ion, naturally occurring in human plasma and urine
• Upregulates collagen I and III synthesis, stimulates TGF-β expression, and activates antioxidant defense genes
• Used in both topical cosmetic formulations (0.5–5% concentrations) and subcutaneous research protocols (1–2 mg/day)
• A 50 mg vial dissolved in 5 mL produces a 10 mg/mL stock solution suitable for topical dilution
• Use the Reconstitution Calculator to prepare your GHK-Cu vial →

⚠️ Disclaimer: This article is intended for educational and research purposes only. GHK-Cu is a research compound and is not approved by the FDA for therapeutic use in humans. All information presented here is drawn from published preclinical and clinical research. Nothing in this article constitutes medical advice. Consult a licensed healthcare professional before use.

GHK-Cu is one of the most well-characterized peptides in the anti-aging and skin research space, yet it remains underappreciated compared to flashier compounds. First identified in human plasma by Loren Pickart in the 1970s, this small tripeptide — Glycine-Histidine-Lysine bound to a copper (II) ion — has since accumulated an unusually broad research base covering wound healing, collagen synthesis, anti-inflammatory signaling, and even neuroprotection. Its dual application in both injectable research and topical cosmetic formulations makes it a unique compound among the peptides studied today.

What makes GHK-Cu particularly interesting is the range of biological activity it exerts despite its small size. Rather than targeting a single receptor, GHK-Cu appears to act as a broad biological signal for tissue remodeling and repair — essentially functioning as a wound-healing messenger that the body itself produces in response to tissue injury. Understanding how this mechanism works, and how to properly prepare and use GHK-Cu in research contexts, is the focus of this guide.

What Is GHK-Cu?

GHK-Cu is a naturally occurring tripeptide-copper complex. The peptide portion — Glycine-Histidine-Lysine (GHK) — was first isolated from human albumin, and researchers later established that its plasma concentration is approximately 200 ng/mL in young adults, declining significantly with age. This age-related decline parallels the well-documented reduction in skin regenerative capacity, leading researchers to hypothesize that GHK-Cu supplementation could partially restore youthful signaling activity.

The copper component is integral to the compound's function. The histidine residue in the peptide has a high affinity for copper (II) ions, forming a stable chelate complex that allows GHK to act as a copper chaperone — transporting and delivering copper to sites where it is needed for enzymatic activity. Copper is a required cofactor for lysyl oxidase, the enzyme responsible for cross-linking collagen and elastin fibers, as well as for superoxide dismutase and cytochrome c oxidase. Without adequate copper delivery, these enzymatic processes are impaired regardless of substrate availability.

GHK-Cu is commercially available in two primary forms for research: lyophilized powder (typically in 5 mg or 50 mg vials for subcutaneous or topical research) and pre-dissolved topical formulations. For injectable research use, the lyophilized form reconstituted in bacteriostatic water is standard. Molecular weight is approximately 340.4 Da for the GHK portion, with the copper complex adding to a total of approximately 403.9 Da.

Mechanism of Action

GHK-Cu's mechanism is multifaceted, which explains both its broad research utility and why it has proven difficult to characterize with a single "target." The compound operates through at least four major pathways that have been identified in peer-reviewed research.

Copper chaperone activity is the most direct mechanism. By delivering copper to sites of tissue remodeling, GHK-Cu facilitates the activity of lysyl oxidase, which catalyzes the cross-linking of lysine and hydroxylysine residues in collagen and elastin precursors. This cross-linking is what gives mature collagen fibrils their tensile strength. In aged skin, this process is impaired not only due to reduced GHK-Cu levels but also due to general copper dysregulation — making copper delivery a meaningful therapeutic target.

Collagen and elastin upregulation has been demonstrated in multiple fibroblast culture studies. GHK-Cu has been shown to increase the synthesis of collagen I, collagen III, and elastin at the gene expression level. A key study published in the Journal of Investigative Dermatology demonstrated that GHK-Cu stimulated collagen synthesis in skin fibroblasts by over 70% compared to controls at concentrations as low as 1 nanomolar. TGF-β1 (transforming growth factor beta-1), a master regulator of extracellular matrix production, is also upregulated — amplifying the collagen-promoting effect beyond what GHK-Cu alone could explain.

Antioxidant gene expression represents another well-documented mechanism. GHK-Cu activates the Nrf2 transcription pathway, which governs the expression of over 200 genes involved in antioxidant defense, including superoxide dismutase (SOD1, SOD2), catalase, and glutathione reductase. Research by Pickart and Margolina published in Biochemical Pharmacology found that GHK-Cu could shift macrophage phenotype from inflammatory (M1) to anti-inflammatory (M2), suggesting relevance not only for wound healing but potentially for inflammatory skin conditions.

VEGF stimulation and angiogenesis is a fourth pathway with implications for wound healing and potentially hair follicle research. GHK-Cu has been shown to upregulate vascular endothelial growth factor (VEGF) expression, promoting the formation of new blood vessels in healing tissue. This vascular support is believed to contribute to GHK-Cu's observed efficacy in wound healing models, where adequate blood supply to the remodeling tissue is a limiting factor.

Topical vs. Subcutaneous Research Use

GHK-Cu occupies an unusual position among research peptides in that it is actively studied through two distinct administration routes, each requiring very different concentration preparations and research designs.

Topical use is the more commercially widespread application. In cosmetic and dermatological research, GHK-Cu is typically formulated at concentrations between 0.5% and 5% by weight. At these concentrations, the peptide is applied directly to the skin surface, where it penetrates the stratum corneum — a process that is facilitated by its small molecular size relative to most active peptide compounds. A 1% solution of GHK-Cu in a 30 mL serum formulation, for example, would contain 300 mg of GHK-Cu total. Multiple published clinical studies using topical GHK-Cu at 1–2% concentrations have reported improvements in skin density, firmness, and fine-line appearance over 12-week study periods.

Subcutaneous research involves much lower absolute doses but achieves much higher localized tissue concentrations. The typical subcutaneous research dose cited in the literature falls between 1 and 2 mg per injection, administered once daily. At this dose level, a 5 mg vial provides a 2.5–5 day supply depending on the protocol. Subcutaneous administration is typically reserved for systemic research applications or for localized tissue injection when studying wound healing or joint inflammation models. The reconstitution math for injectable use is therefore quite different from the large-volume dilutions required for topical formulations.

It is worth noting that both routes have legitimate research applications — they are not interchangeable. A topical preparation intended for skin surface application should not be used for injection (the preservatives or carrier compounds in many topical formulations are not suitable for parenteral use). Conversely, a bacteriostatic-water-reconstituted injectable preparation can, in principle, be used topically, but is not optimized for skin penetration without appropriate carrier formulation.

Reconstitution Math for Injectable Research

For subcutaneous research use, GHK-Cu is typically supplied as a lyophilized powder in 5 mg vials. The goal is to produce a concentration that allows accurate dosing with a standard insulin syringe. The table below covers the three most common reconstitution scenarios for a 5 mg vial.

For most subcutaneous injection protocols, the 2.0 mL reconstitution (2.5 mg/mL) offers the best balance between syringe accuracy and total volume per injection. A 1 mg dose requires 40 units on a 100-unit insulin syringe — a comfortable, easily measurable volume. The 5.0 mL dilution results in an injection volume that is too large for typical subcutaneous use (1 mL per injection is the general upper limit for subQ).

Always inject the bacteriostatic water slowly down the side of the vial, not directly onto the powder. Gently swirl — never shake — until the peptide is fully dissolved. GHK-Cu dissolves readily in most cases due to its small size and relatively high water solubility. Reconstituted vials should be stored at 2–8°C and are typically stable for 4–6 weeks when handled correctly.

Calculate your exact GHK-Cu dose and volume →

Topical Solution Preparation

For topical research applications, the concentration calculations work differently. Rather than targeting a per-injection dose, researchers typically aim for a percentage concentration within a final formulation volume.

To prepare a 1% GHK-Cu solution in 10 mL of carrier (such as a water-glycerin base or simple saline):

• 1% of 10,000 mg = 100 mg of GHK-Cu required
• Dissolve 100 mg of GHK-Cu in a small volume of sterile water first, then bring to final volume with carrier

For a more concentrated 3% stock solution that can be diluted into finished products:

• Per 10 mL: 300 mg GHK-Cu
• Per 30 mL: 900 mg GHK-Cu (approximately one standard 1g research vial)

The penetration of GHK-Cu through the skin is enhanced when the formulation pH is kept between 4.5 and 6.5 — the peptide is more stable and more skin-compatible in this mildly acidic range. Pairing GHK-Cu with hyaluronic acid as a carrier base is a common research formulation strategy, as hyaluronic acid improves surface hydration and may facilitate penetration. Avoid formulations with high concentrations of alcohols, which can destabilize the peptide-copper complex.

How GHK-Cu Compares to Argireline and Matrixyl

GHK-Cu is frequently discussed alongside two other prominent anti-aging peptides: Argireline (Acetyl Hexapeptide-3) and Matrixyl (Palmitoyl Pentapeptide-4). While all three are studied for skin rejuvenation, their mechanisms and applications are meaningfully different.

Argireline works through a fundamentally different pathway — it mimics the N-terminus of SNAP-25, competing with the SNARE complex and thereby partially inhibiting the neurotransmitter release that causes muscle contraction. The result is a mild botulinum-toxin-like relaxation effect on expression lines. It has no direct effect on collagen synthesis. Matrixyl, by contrast, operates as a matrikine — a fragment of the extracellular matrix that signals fibroblasts to produce more collagen, acting as a feedback signal of matrix degradation. Its effective concentration is much lower than GHK-Cu, but its mechanism is purely fibroblast-stimulatory without the copper delivery or antioxidant components.

GHK-Cu's advantage over both is the breadth of its biological activity: it addresses collagen synthesis, antioxidant defense, angiogenesis, and anti-inflammatory signaling simultaneously. Combining GHK-Cu with Matrixyl in topical formulations is a common research strategy, as the two compounds work through complementary pathways. Combining GHK-Cu with Argireline is also rational for formulations targeting both expression lines and overall skin quality.

Storage Notes

Before reconstitution (lyophilized): GHK-Cu peptide powder should be stored at -20°C for long-term storage (up to 24 months) or at 4°C for short-term storage (up to 6 months). Keep vials away from light and moisture. Lyophilized GHK-Cu is relatively stable compared to many peptides due to its small size and lack of disulfide bonds, but proper cold storage is still essential for maintaining research-grade quality.

After reconstitution (injectable, BAC water): Store at 2–8°C (standard refrigerator temperature). Reconstituted GHK-Cu in bacteriostatic water is typically stable for 4–6 weeks under these conditions. Bacteriostatic water's benzyl alcohol content inhibits microbial growth, extending the usable window compared to sterile water reconstitution (which should be used within 24–48 hours). Never freeze reconstituted peptide solutions — the freeze-thaw cycle can degrade the peptide and promote aggregation.

Topical preparations: Once formulated into a topical solution or serum base, GHK-Cu is generally stable for 3–6 months when stored away from direct light and heat. Refrigeration is recommended but not strictly required for most carrier formulations. pH stability (4.5–6.5) is a more important factor than temperature for topical GHK-Cu stability.

Signs of degradation to watch for include: color change (fresh GHK-Cu in solution is typically light blue due to the copper complex; discoloration or browning suggests degradation), cloudiness or visible precipitate in what should be a clear solution, and off-odors. If any of these signs are present, the compound should not be used in research.

Explore the full GHK-Cu database entry →

Conclusion

GHK-Cu stands out in the peptide research landscape for its well-documented mechanisms, its dual utility in injectable and topical applications, and its unusually broad range of biological effects for such a small molecule. The copper chaperone mechanism, combined with TGF-β stimulation, Nrf2 activation, and VEGF upregulation, makes it one of the most mechanistically interesting compounds in the anti-aging peptide category.

Whether your research involves subcutaneous injection protocols at 1–2 mg/day or topical formulations at 1–5% concentration, accurate preparation is essential. Use the reconstitution calculator to verify your math before preparing any vial, and consult the full database entry for additional citations and purity sourcing notes.

This content is intended for research and educational purposes only. GHK-Cu is not approved for therapeutic use in humans. All research use should comply with applicable regulations and institutional guidelines.

Frequently Asked Questions About GHK-Cu

Q: What does GHK-Cu do for skin? A: GHK-Cu stimulates collagen I and III synthesis by upregulating TGF-β1 expression in skin fibroblasts — a key study in the Journal of Investigative Dermatology showed over 70% increase in collagen synthesis at concentrations as low as 1 nanomolar. It also activates the Nrf2 antioxidant defense pathway, promotes VEGF-driven angiogenesis for improved skin vascularity, and shifts macrophage phenotype toward anti-inflammatory M2, collectively supporting skin density, firmness, and wound healing.

Q: Is GHK-Cu better used topically or subcutaneously? A: Both routes have legitimate but distinct research applications. Topical use at 0.5–5% concentrations is appropriate for skin surface research — multiple 12-week clinical studies at 1–2% have reported improvements in skin density and fine-line appearance. Subcutaneous injection at 1–2 mg/day achieves higher systemic and localized tissue concentrations and is used for wound healing and joint inflammation models. The routes are not interchangeable; topical formulations should never be injected due to carrier compounds not suitable for parenteral use.

Q: What is the typical GHK-Cu research dose for subcutaneous injection? A: The typical injectable research dose is 1–2 mg per injection administered once daily. A 5 mg vial provides a 2.5–5 day supply at this dose range. The most practical reconstitution is 2.0 mL of bacteriostatic water into a 5 mg vial, yielding 2.5 mg/mL — a 1 mg dose then requires 40 units (0.4 mL) on a 100-unit insulin syringe, a comfortable and accurately measurable volume.

Q: How do you reconstitute GHK-Cu for injection? A: Add bacteriostatic water slowly down the inner wall of the vial — not directly onto the powder — and gently swirl until fully dissolved. GHK-Cu dissolves readily due to its small size (approximately 403.9 Da including the copper complex) and high water solubility. Store the reconstituted vial at 2–8°C; it is typically stable for 4–6 weeks in bacteriostatic water. The blue tint of a freshly reconstituted GHK-Cu solution is normal and reflects the copper-peptide complex.

Q: How does GHK-Cu compare to Argireline and Matrixyl? A: GHK-Cu has the broadest mechanism of the three: it addresses collagen synthesis, antioxidant defense, angiogenesis, and anti-inflammatory signaling simultaneously through copper chaperone activity and TGF-β/Nrf2 upregulation. Argireline (Acetyl Hexapeptide-3) works by mimicking SNAP-25 to partially inhibit neuromuscular signaling at expression lines — it has no direct effect on collagen synthesis. Matrixyl (Palmitoyl Pentapeptide-4) acts as a matrikine to stimulate fibroblast collagen production at very low concentrations (0.02–0.1%); combining it with GHK-Cu covers complementary pathways and is a common research formulation strategy.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions